These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25812501)

  • 1. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
    Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
    Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
    Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
    Hegerova LT; Leal AD; Grendahl DC; Seisler DK; Sorgatz KM; Anderson KJ; Hilger CR; Loprinzi CL
    Support Care Cancer; 2015 Jan; 23(1):55-9. PubMed ID: 24964876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
    Pritchett W; Kinsley K
    Clin J Oncol Nurs; 2016 Oct; 20(5):555-6. PubMed ID: 27668376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
    Leal AD; Kadakia KC; Looker S; Hilger C; Sorgatz K; Anderson K; Jacobson A; Grendahl D; Seisler D; Hobday T; Loprinzi CL
    Support Care Cancer; 2014 May; 22(5):1313-7. PubMed ID: 24402411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
    Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
    Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
    J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
    Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
    Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
    Kameda K; Kiba T; Ogawa Y; Kimoto S; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1255-7. PubMed ID: 25335710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
    Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of heparin to lower the incidence of phlebitis induced by anti-neoplastic agents used in ovarian cancer.
    Ikeda S; Douchi T; Nagata Y
    J Obstet Gynaecol Res; 2004 Dec; 30(6):427-9. PubMed ID: 15566456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
    Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
    Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
    Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
    J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.